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Reduced cardiovascular capacity and resting metabolic rate in men with
prostate cancer undergoing androgen deprivation: a comprehensive cross-
sectional investigation
Abstract
Objectives. To investigate if androgen deprivation therapy exposure is associated with additional risk factors
for cardiovascular disease and metabolic treatment-related toxicities. Methods. One hundred and seven men
(42-89 years) with prostate cancer undergoing androgen deprivation therapy completed a maximal graded
objective exercise test to determine maximal oxygen uptake, assessments for resting metabolic rate, body
composition, blood pressure and arterial stiffness, and blood biomarker analysis. A cross-sectional analysis
was undertaken to investigate the potential impact of therapy exposure with participants stratified into two
groups according to duration of androgen deprivation therapy (≥3 months). Results. Maximal oxygen uptake
(26.1 ± 6.0 mL/kg/min versus 23.2 ± 5.8 mL/kg/min, ) and resting metabolic rate (1795 ± 256 kcal/d versus
1647 ± 236 kcal/d, ) were significantly higher in those with shorter exposure to androgen deprivation. There
were no differences between groups for peripheral and central blood pressure, arterial stiffness, or metabolic
profile. Conclusion. Three months or longer exposure to androgen deprivation therapy was associated with
reduced cardiorespiratory capacity and resting metabolic rate, but not in a range of blood biomarkers. These
findings suggest that prolonged exposure to androgen deprivation therapy is associated with negative
alterations in cardiovascular outcomes. Trial registry is: ACTRN12609000200280.
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Objectives. To investigate if androgen deprivation therapy exposure is associated with additional risk factors for cardiovascular
disease and metabolic treatment-related toxicities. Methods. One hundred and seven men (42–89 years) with prostate cancer
undergoing androgen deprivation therapy completed a maximal graded objective exercise test to determine maximal oxygen
uptake, assessments for resting metabolic rate, body composition, blood pressure and arterial stiffness, and blood biomarker
analysis. A cross-sectional analysis was undertaken to investigate the potential impact of therapy exposure with participants
stratified into two groups according to duration of androgen deprivation therapy (<3 months and ≥3 months). Results. Maximal
oxygen uptake (26.1 ± 6.0mL/kg/min versus 23.2 ± 5.8mL/kg/min, 𝑝 = 0.020) and resting metabolic rate (1795 ± 256 kcal/d versus
1647 ± 236 kcal/d, 𝑝 = 0.005) were significantly higher in those with shorter exposure to androgen deprivation. There were no
differences between groups for peripheral and central blood pressure, arterial stiffness, or metabolic profile. Conclusion. Three
months or longer exposure to androgen deprivation therapy was associated with reduced cardiorespiratory capacity and resting
metabolic rate, but not in a range of blood biomarkers. These findings suggest that prolonged exposure to androgen deprivation
therapy is associated with negative alterations in cardiovascular outcomes. Trial registry is: ACTRN12609000200280.
1. Introduction
Androgen deprivation therapy (ADT) is a commonly used
treatment for prostate cancer [1]. Although ADT improves
prostate cancer survival, a number of studies have reported
associations between ADT and treatment-related toxicities,
such as increased risk of cardiovascular disease (CVD) and
metabolic complications which can compromise survival
and quality of life [2–4]. Moreover, several toxicities have
been reported to be present soon after initiation of treat-
ment. For example, increased arterial stiffness and adverse
body compositional changes were associated with increasing
insulin concentrations after 6 months of ADT treatment
suggestive of impaired insulin sensitivity [5], and others
have reported increases in serum insulin levels after only 3
months ofADTexposure [6]. ADT-related decline in physical
function, grip strength, and self-reported physical function
has been previously reported by Alibhai et al. [7] when
comparedwith non-ADT controls; ADT users also hadworse
role physical function, bodily pain, and vitality. Importantly,
these reductions in objective and self-reported measures of
physical function were apparent within the first 3 months of
initiating ADT treatment and persisted for at least 12 months.
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Metabolic implications of long-term ADT have been
previously explored by Basaria et al. [3], who found men
receiving >12 months ADT developed insulin resistance and
hyperglycaemia, independent of age and body mass index
(BMI). In addition, long-term ADT has been associated with
diabetes and metabolic syndrome [8]. Keating et al. [9] were
the first to report higher risks of cardiovascular andmetabolic
complications as well as sudden cardiac death in prostate can-
cer patients receiving ADT, whilst short-termADT treatment
was significantly associated with greater risks of disease and
the elevated risks persisted inmen on longer duration therapy
[9]. Given the association between cardiorespiratory fitness
andCVDmortality [10], themeasurement of aerobic capacity
can significantly improve the risk classification for CVD
mortality [11]. While previous research has predominantly
used surrogate measures of cardiorespiratory fitness such
as the six-minute walk test (6MWT) or 400m walk [7,
12], directly assessing aerobic capacity in ADT-treated men
will further our understanding of the cardiovascular risks
associatedwith this formof treatment. In this study, we report
for the first time potential differences in relation to patients
ADT exposure using objective measures of aerobic capacity,
resting metabolic rate, blood pressure, arterial stiffness, and
blood biomarkers. We hypothesized that longer-term ADT
would lead to compromised aerobic capacity and metabolic
parameters hence posing a greater risk for the development
and progression of cardiovascular and metabolic diseases.
2. Methods
2.1. Participants. 272 patients with prostate cancer were
screened for participation in a 12-month exercise trial [13]
from February 2009 to August 2011 in Perth, Western Aus-
tralia, and Brisbane, Queensland. 109 patients declined par-
ticipation or were excluded for the following main reasons:
declined to participate, too far to travel, unable to fit in
with work, unable to obtain general practitioner/physician
consent, and bone metastatic disease. In this report, we
present the results from baseline assessment of a subgroup
of 107 patients who undertook testing including cardiores-
piratory capacity by October 2010. This study was approved
by the University Human Research Ethics Committee and all
participants provided signed informed consent.
All participants underwent assessment for cardiorespi-
ratory capacity, resting metabolic rate, peripheral and cen-
tral blood pressure and arterial stiffness, and markers of
metabolic health.
2.2. Cardiorespiratory Capacity. Participants performed a
standardised progressive maximal walking test (Bruce Pro-
tocol) on a motorized treadmill supervised by a physician.
Expired respiratory gases were collected (Parvo Metabolic
Measuring System, Sandy, UT, USA) to determine maximal
oxygen uptake (the maximal amount of oxygen that can
be consumed and utilised, VO
2max). A plateau in oxygen
consumption was used as the criterion for achieving VO
2max;
if no plateau occurred, then a respiratory exchange ratio
(RER) of ≥1.1 was used. If the subject achieved no plateau
in oxygen consumption or a RER value < 1.1 their data were
excluded. This direct assessment of peak oxygen consump-
tion is considered the gold standard outcome of cardiores-
piratory fitness or aerobic capacity [14]. The coefficient of
variation for repeatedmaximal exercise tests is approximately
4% [15]. Blood pressure was measured during the last minute
of each 3-minute stage via manual auscultatory technique.
2.3. Resting Metabolic Rate. Resting metabolic rate (RMR)
was measured via respiratory gas analysis over 20 minutes. A
5-minute period that showed an oxygen consumption with a
coefficient of variation of <10% was selected for analysis [16].
The coefficient of variation for RMR is <3%.
2.4. Resting Blood Pressure and Arterial Stiffness. Brachial
blood pressure was recorded at the dominant arm in triplicate
via a validated oscillometric device (HEM-705CP, Omron
Corporation, Japan) [17]. Applanation tonometry (SPC-301,
Millar Instruments, Houston, Texas, USA) was used to
measure radial artery pressure waveforms at the right arm. A
generalised transfer functionwas applied to obtain the central
pressurewaveformat the ascending aorta. Pulsewave analysis
was used to determine central blood pressure and indices
of arterial stiffness, performed using SphygmoCor version
6.1 software (AtCor Medical, Sydney, Australia). Assessing
central blood pressure using this method has been validated
against invasive techniques [18]. The augmentation index
(AIx) refers to the ratio of augmentation to central pulse
pressure, expressed as a percentage, and measures systemic
arterial stiffness. Variability has been previously reported
as 0.3mmHg for central systolic pressure and 1.5% for the
AIx. Carotid-to-radial pulse wave velocity was measured
by collecting arterial pressure waves at both the carotid
and radial locations. The reported coefficient of variation
for forearm (radial) pulse wave velocity is 2.9% whilst the
brachial pulse wave velocity coefficient of variation is 7.7%
[19].
2.5. Metabolic Syndrome. Patients were classified as having
metabolic syndrome if theymet three of the following five cri-
teria according to the Adult Panel III Criteria [20]: (1) plasma
glucose level more than 110mg/dL, (2) serum triglyceride
levels ≥150mg/dL, (3) serum high density lipoprotein less
than 40mg/dL, (4) waist circumference greater than 102 cm,
and (5) blood pressure ≥135/80mmHg. Patients on antihy-
pertensive and antilipid medications were also considered
positive for the respective criterion.
2.6. OtherMeasures. Venous blood samples (2× 8.5mL)were
obtained from the antecubital veinwithwhole blood analysed
for haemoglobin A1C (HbA1C, %) whilst the remaining
blood was separated and analysed for testosterone, insulin,
prostate specific antigen, triglycerides, LDL cholesterol, HDL
cholesterol, total cholesterol, glucose, and C-reactive protein.
All blood variables were analysed commercially by accredited
Australian National Association of Testing Authorities labo-
ratories (Pathwest Laboratory Medicine, WA).
Whole body bone mineral-free lean mass and fat mass,
trunk fat, and body fat percentage were assessed by dual
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Table 1: Subject characteristics for the short- and longer-term androgen deprivation groups.
Variable
<3 months
Mean ± SD
𝑛 = 57
≥3 months
Mean ± SD
𝑁 = 50
Mean difference (95% CI) 𝑝 value
Age (years) 67.6 ± 8.9 69.9 ± 9.7 −2.3 (−5.9, 1.3) 0.395
Prostate specific antigen (ng⋅mL−1) 1.2 ± 1.7 1.4 ± 2.6 −0.2 (−1.1, 0.7) 0.659
Gleason Score 7.6 ± 0.8 7.7 ± 1.4 −0.1 (−0.6, 0.6) 0.985
Testosterone (pg⋅mL−1) 1.3 ± 1.5 1.5 ± 3.4 −0.2 (−1.2, 0.8) 0.651
Height (cm) 172.2 ± 6.4 172.7 ± 6.3 −0.5 (−3.2, 2.1) 0.648
Body mass (kg) 85.7 ± 13.6 83.4 ± 14.0 2.3 (−3.1, 7.8) 0.105
Body mass index (kg⋅m2) 28.9 ± 4.3 28.0 ± 3.9 0.9 (−0.7, 2.4) 0.215
Waist circumference (cm) 99.2 ± 12.1 100.3 ± 12.9 −0.9 (−5.5, 3.9) 0.737
energy X-ray absorptiometry (DEXA, Hologic Discovery A,
Waltham, MA, USA). In addition, appendicular lean mass
was calculated as the sum of upper and lower limb lean mass.
The coefficient of variation for body composition measures is
<1%.
2.7. Statistical Analysis. Sample size calculations for the initial
RCT [13] resulted in a requirement for 65 subjects per group
at the commencement of the study. For the principal analyses
in this report, we had 80% power to detect a significant
difference in METS and similarly for VO
2max in absolute
(L/min) and relative terms (mL/kg/min), and 87% for RMR
in kcal/24 hr.
Analyses were performed using the Statistical Package
for Social Sciences version 18.0 software (PASW, Chicago,
IL, USA). Normality of the data was assessed using the
Kolmogorov-Smirnov test. The analyses included standard
descriptive statistics, Student’s independent 𝑡-tests, and Pear-
son’s chi-square test for categorical variables. Potential differ-
ences between patients on <3 months or ≥3 months on ADT
were undertaken based on the previous prospective work by
Alibhai and colleagues [7] which showed that even short-
term treatment leads to substantial deterioration in physical
function. All tests were two-tailed and an alpha level of 0.05
was applied as the criterion for statistical significance. Results
are reported as the mean ± standard deviation.
3. Results
3.1. Subject Characteristics. Characteristics for all partici-
pants were age 68.6 ± 8.8 kg; height 172.4 ± 6.3 cm; and
body mass 84.0 ± 13.7 kg. Mean ADT duration was 2.0 ± 0.0
and 7.1 ± 6.2 months for the shorter and longer groups,
respectively. There were no significant differences in any
subject characteristics (Table 1) or lean and fat mass (Table 2)
based on ADT exposure.
3.2. Cardiorespiratory Capacity. 91 (85%) of the participants
were able to achieve the desired criteria for VO
2max with
no difference between groups in their ability to achieve
VO
2max. Maximal oxygen consumption was significantly
higher in the shorter ADT duration group when presented
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Figure 1: Absolute VO
2max values (mean ± SE) for the short- and
longer-term androgen deprivation groups. ∗ denotes significant
difference versus <3 months.
in absolute (L/min−1) (𝑝 = 0.035) (Figure 1) or relative
terms (mL/kg/min−1) (𝑝 = 0.020) (Table 3). Corresponding
metabolic equivalents were also significantly higher in the
shorter duration ADT group (𝑝 = 0.02). Whilst test
duration was not statistically significant, shorter duration
group exhibited an additional 54 seconds (𝑝 = 0.080) of
walking endurance.
3.3. RestingMetabolic Rate. There was a significant difference
observed in RMR with the shorter duration group recording
a significantly higher (𝑝 = 0.005) RMR in absolute terms
and relative to body mass RMR (𝑝 = 0.017) compared to
the longer duration group (Table 3). Whilst not statistically
significant (𝑝 = 0.079), RMR relative to lean body mass
was 1.3 kcal/lean kg/24 hr higher in those with shorter ADT
exposure.
3.4. Central Blood Pressure. There were no differences bet-
ween short and longer ADT exposure in any of the central or
peripheral blood pressure variables or central augmentation
index (Table 3). Further, therewas no difference in pulse wave
velocity between groups (Table 3).
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Table 2: Body composition and blood markers for the short- and longer-term androgen deprivation groups.
Variable
<3 months
Mean ± SD
𝑛 = 57
≥3 months
Mean ± SD
𝑁 = 50
Mean difference (95% CI) 𝑝 value
Lean tissue mass (kg)
Whole body 60.1 ± 7.5 58.0 ± 8.6 2.1 (−1.0, 5.2) 0.184
Appendicular 25.6 ± 3.3 24.5 ± 3.9 1.1 (−0.3, 2.5) 0.112
Fat mass (kg)
Whole body 23.1 ± 7.3 24.6 ± 8.3 −1.5 (−4.5, 1.4) 0.307
Trunk 12.4 ± 4.5 12.9 ± 5.8 −0.5 (−2.5, 1.5) 0.627
Body fat % 26.4 ± 5.1 28.3 ± 5.2 −1.9 (−4.0, 0.1) 0.053
Blood markers
HbA1C (%) 6.4 ± 3.7 6.1 ± 1.0 0.3 (−0.8, 1.3) 0.638
Testosterone (pg⋅mL−1) 1.3 ± 1.5 1.5 ± 3.4 −0.2 (−1.2, 0.8) 0.651
Prostate specific antigen (ng⋅mL−1) 1.2 ± 1.7 1.4 ± 2.6 −0.2 (−1.1, 0.7) 0.659
Insulin (mU/L) 11.2 ± 6.7 9.2 ± 4.3 2.0 (−0.3, 4.2) 0.085
Triglycerides (mmol/L) 1.3 ± 0.6 1.4 ± 0.7 −0.1 (−0.3, 0.1) 0.393
LDL cholesterol (mmol/L) 2.8 ± 0.9 2.9 ± 1.0 −0.1 (−0.5, 0.3) 0.575
HDL cholesterol (mmol/L) 1.3 ± 0.4 1.4 ± 0.4 −0.1 (−0.3, 0.1) 0.269
Total cholesterol (mmol/L) 4.7 ± 1.1 4.9 ± 1.0 −0.2 (−0.6, 0.2) 0.287
Glucose (mmol/L) 5.5 ± 1.1 5.9 ± 1.9 −0.4 (−1.0, 0.2) 0.216
C-reactive protein (mg/L) 2.9 ± 3.3 2.5 ± 2.0 0.4 (−0.7, 1.5) 0.469
HbA1C: glycated haemoglobin; LDL: low density lipoprotein; HDL: high density lipoprotein.
3.5. Metabolic Profile. No significant differences were obser-
ved between short and longer ADT exposure in any of the
blood markers analysed (Table 2). Whilst not statistically
significant, insulin was 19.6% higher in the shorter duration
group (𝑝 = 0.085).
3.6. Metabolic Syndrome Variables. According to National
Cholesterol Education Program Adult Treatment Panel III,
20.3% of the acute group and 13.5% of the chronic group were
classified as having metabolic syndrome (𝑝 = 0.337). How-
ever, there were no significant differences observed between
groups for fasting plasma glucose (𝑝 = 0.998), serum
triglycerides (𝑝 = 0.874), serum HDL (𝑝 = 0.815), waist
circumference (𝑝 = 0.994), or hypertension (𝑝 = 0.093).
4. Discussion
We examined the difference between patients on either short-
or longer-term ADT across a variety of cardiovascular and
metabolic parameters to determine if additional therapy time
exposure is associated with accumulating CVD risk factors
or metabolic treatment-related toxicities. Those exposed to
ADT for a longer period of time had a lower cardiorespiratory
capacity and RMR suggesting that longer ADT duration is
associatedwith decline in cardiovascular capacity and aspects
of metabolic function.
The maximal aerobic exercise testing protocol used in
this study has been shown to be safe and feasible in this
population [21]. To our knowledge, this is the first research
study to directly measure VO
2max in men on ADT to investi-
gate the effect duration of treatment has on cardiorespiratory
capacity. Our findings demonstrate that there are differences
in cardiorespiratory capacity between men on shorter- and
longer-term ADT. The VO
2max of the shorter duration ADT
group was 21% higher than the longer exposed group, which
has important implications when considering that the low
levels of cardiorespiratory fitness have been associated with
a markedly increased risk of premature death from all causes
and in particular CVD in all populations including healthy
older men and those with established cardiovascular disease
[10]. Conversely, an increase in cardiorespiratory fitness is
associated with a reduced risk of CVD [22]. No differences
were observed in any of the blood pressure parameters in
relation to ADT exposure.
ADT exposure time appears to influence resting energy
expenditure with those men on longer duration ADT having
a lower RMR. Fat-free mass plays a major role in the variance
of RMR amongst individuals [23], with more recent research
suggesting that both fat-free mass and fat mass significantly
influence RMR [24]. Whilst no significant differences in any
body composition values were reported, it is likely that the
combined effects of the nonsignificant differences in lean
body mass (2 kg) and fat mass (1.5 kg) contributed to this sig-
nificant reduction in resting energy expenditure in the longer
ADT exposure group. A reduced RMR with continuing ADT
exposure would contribute to the accumulation of adipose
tissue if dietary intake remained unchanged.
When exploring additional CVD risk factors, metabolic
syndrome has been widely used as a surrogate marker for
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Table 3: Resting andmaximal cardiorespiratory values and hemodynamic and pulse wave analysis parameters for the short- and longer-term
androgen deprivation groups.
Variable
<3 months
Mean ± SD
𝑛 = 57
≥3 months
Mean ± SD
𝑁 = 50
Mean difference (95% CI) 𝑝 value
VO
2max (L/min
−1)∗ 2.3 ± 1.0 1.9 ± 0.6 0.4 (0.1, 0.7) 0.035
VO
2max (mL/kg/min
−1)∗ 26.1 ± 6.0 23.2 ± 5.8 2.9 (0.5, 5.3) 0.020
VO
2max (METS)
∗ 7.5 ± 1.7 6.6 ± 1.6 0.9 (0.1, 1.5) 0.020
Test duration (mins) 8.5 ± 2.8 7.6 ± 2.6 0.9 (−0.1, 2.1) 0.080
Resting metabolic rate
(kcal/24 hr)∗ 1795 ± 256 1647 ± 236 147 (46, 249) 0.005
Relative total body mass
Resting metabolic rate
(kcal/kg/24 hr)∗
21.5 ± 3.0 20.0 ± 2.6 1.5 (0.3, 2.7) 0.017
Relative lean body mass
Resting metabolic rate
(kcal/lean kg/24 hr)
30.5 ± 3.2 29.2 ± 4.1 1.3 (−0.2, 2.9) 0.079
Peripheral SBP (mmHg) 150.9 ± 19.9 149.0 ± 19.4 1.9 (−5.8, 9.6) 0.624
Peripheral DBP (mmHg) 85.6 ± 12.1 84.5 ± 10.4 1.1 (−3.4, 5.6) 0.626
Peripheral MAP (mmHg) 108.4 ± 15.0 107.2 ± 12.8 1.2 (−4.3, 6.7) 0.669
Central SBP (mmHg) 139.1 ± 21.1 138.7 ± 20.2 0.4 (−7.7, 8.5) 0.922
Central DBP (mmHg) 86.8 ± 12.3 85.5 ± 10.6 1.3 (−3.2, 5.8) 0.571
Central MAP (mmHg) 108.9 ± 16.1 107.2 ± 12.8 1.7 (−4.1, 7.5) 0.557
Peripheral augmentation
index (AIx, %) 83.5 ± 13.0 86.5 ± 13.9 −3.0 (−8.3, 2.3) 0.261
Central augmentation
pressure (mmHg) 15.4 ± 8.2 16.7 ± 9.6 −1.3 (4.8, 2.1) 0.445
Augmentation load
(mmHg) 14.3 ± 5.0 14.6 ± 4.9 −0.3 (−2.3, 1.6) 0.732
Central augmentation
index (AIx, %) 140.4 ± 17.8 144.4 ± 19.6 −4.0 (−11.3, 3.3) 0.281
Pulse wave velocity (m/s) 10.0 ± 1.4 10.0 ± 1.8 0.0 (−0.6, 0.7) 0.983
VO2max: maximal oxygen uptake; METS: metabolic equivalents; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; AIx:
augmentation index.
∗refers to a significant difference between <3 months and ≥3 months.
CVD. In our study, 20.3% and 13.5% of the shorter and
longer ADT exposure groups, respectively, met the criteria
for metabolic syndrome.These values are lower than the 55%
of ADT-treated prostate cancer patients previously reported
by Braga-Basaria et al. [25] but similar to non-ADT-treated
prostate cancer patients (22%) and control subjects (20%)
reported in the same study [25]. Waist circumference and
hypertension appear to be the two most common cardiovas-
cular risk factors present in both groups, demonstrating that
these risk factors are present irrespective of the treatment
duration.
Whilst not measured in the present study, physical activ-
ity levels are known to exert large influences on aerobic
capacity and functional performance. Previous research in
breast cancer patients has demonstrated that physical activity
levels are significantly reduced following cancer diagnosis
and during treatment [26, 27] and these reductions in
physical activity negatively alter energy balance. We have
recently reported that only∼12%ofAustralian prostate cancer
survivors are meeting sufficient exercise levels (150min of
moderate intensity or 75min of strenuous exercise per week
and twice weekly resistance exercise) [28]. It is possible that
in the current study physical activity levels were reduced
following diagnosis and either they continued to decline as
treatment time progressed or the side effects associated with
declining physical activity levels did not present until later
in treatment which may have contributed to the differences
observed in aerobic fitness and RMR.
It was somewhat surprising that we observed no differ-
ences in the measured blood biomarkers or central blood
pressure in relation to ADT exposure. With regard to the
blood biomarkers, it may be that testosterone suppression has
such a rapid effect, shown by the increased serum insulin
levels previously reported by Dockery et al. [6] after only
3 months of ADT, which leads us to believe that these
biomarkers may have stabilised within the first three months.
The strength of this study is that we directly measured
VO
2
during a maximum exercise stress test (gold standard
assessment for aerobic capacity) rather than use of surrogate
measures such as the 400 meters or 6MWT as well as
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assessments of RMR and central blood pressure. A limitation
of this study is that patients were only assessed at a single
time point during their treatment; hence, we were unable
to continually monitor each participant as treatment time
progressed. Further, the cross-sectional nature of the study
does not permit us to infer causality; however, it provides
initial evidence of decline in aerobic capacity measured
objectively and it could be clinically meaningful to patients
but needs further validation in prospective studies. However,
it should be recognised thatmen in this studywere volunteers
for an exercise trial and therefore are not representative of
all men with prostate cancer undergoing ADT. Lastly, given
the exploratory nature of the study, we did not adjust for
multiple comparisons [29] and, as a result, cannot discount
the possibility that 1-2 of the significant differences may have
been a chance finding.
5. Conclusion
In conclusion, we found that patients exposed to longer
duration ADT had reduced cardiorespiratory capacity and
RMR and these could have clinical meaningful implica-
tions. The exact mechanisms remain unclear as to why
these cardiovascular parameters are further declining as the
treatment time progresses and should be determined in
futuremechanistic studies. Intervention strategies to preserve
cardiovascular capacity and RMR such as exercise medicine
interventions have significant potential to counteract these
forms of decline.
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